ZA200601414B - Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases - Google Patents
Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases Download PDFInfo
- Publication number
- ZA200601414B ZA200601414B ZA200601414A ZA200601414A ZA200601414B ZA 200601414 B ZA200601414 B ZA 200601414B ZA 200601414 A ZA200601414 A ZA 200601414A ZA 200601414 A ZA200601414 A ZA 200601414A ZA 200601414 B ZA200601414 B ZA 200601414B
- Authority
- ZA
- South Africa
- Prior art keywords
- sodium chloride
- agent
- substance
- skin
- coated
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims description 27
- 210000003499 exocrine gland Anatomy 0.000 title claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 18
- 201000010099 disease Diseases 0.000 title description 13
- 239000000203 mixture Substances 0.000 title description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 148
- 239000011780 sodium chloride Substances 0.000 claims description 75
- 239000003814 drug Substances 0.000 claims description 64
- 229940079593 drug Drugs 0.000 claims description 52
- 239000000126 substance Substances 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 38
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 28
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 26
- 229960003105 metformin Drugs 0.000 claims description 26
- 239000006187 pill Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 18
- 239000013078 crystal Substances 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 16
- 229960004889 salicylic acid Drugs 0.000 claims description 15
- 239000011734 sodium Substances 0.000 claims description 15
- 239000000454 talc Substances 0.000 claims description 15
- 229910052623 talc Inorganic materials 0.000 claims description 15
- 229920002261 Corn starch Polymers 0.000 claims description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 14
- 235000013871 bee wax Nutrition 0.000 claims description 14
- 239000012166 beeswax Substances 0.000 claims description 14
- 239000008120 corn starch Substances 0.000 claims description 14
- 229940099112 cornstarch Drugs 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 14
- 229910052708 sodium Inorganic materials 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 14
- 239000001993 wax Substances 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000011505 plaster Substances 0.000 claims description 10
- 235000017663 capsaicin Nutrition 0.000 claims description 9
- 229960002504 capsaicin Drugs 0.000 claims description 9
- 230000007257 malfunction Effects 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 8
- 239000000919 ceramic Substances 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000000774 hypoallergenic effect Effects 0.000 claims description 6
- 239000011859 microparticle Substances 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 210000004082 barrier epithelial cell Anatomy 0.000 claims description 4
- 230000004890 epithelial barrier function Effects 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000007894 caplet Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 229960002668 sodium chloride Drugs 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 230000008384 membrane barrier Effects 0.000 claims description 2
- 240000007673 Origanum vulgare Species 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 description 68
- 210000003491 skin Anatomy 0.000 description 44
- 241001448624 Miliaria Species 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 210000004243 sweat Anatomy 0.000 description 18
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 13
- 206010020772 Hypertension Diseases 0.000 description 13
- 229960001138 acetylsalicylic acid Drugs 0.000 description 13
- 210000000106 sweat gland Anatomy 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 229940092738 beeswax Drugs 0.000 description 11
- 230000004087 circulation Effects 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 11
- 208000007530 Essential hypertension Diseases 0.000 description 9
- 206010027627 Miliaria Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 208000003251 Pruritus Diseases 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 206010052804 Drug tolerance Diseases 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 230000026781 habituation Effects 0.000 description 7
- 240000004160 Capsicum annuum Species 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 4
- 235000002283 Capsicum annuum var aviculare Nutrition 0.000 description 4
- 235000013303 Capsicum annuum var. frutescens Nutrition 0.000 description 4
- 235000002284 Capsicum baccatum var baccatum Nutrition 0.000 description 4
- 235000002568 Capsicum frutescens Nutrition 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 238000000586 desensitisation Methods 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 201000002692 miliaria profunda Diseases 0.000 description 4
- 201000004169 miliaria rubra Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000001823 pruritic effect Effects 0.000 description 4
- 201000004700 rosacea Diseases 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000006443 lactic acidosis Diseases 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000026072 Motor neurone disease Diseases 0.000 description 2
- 206010036049 Polycystic ovaries Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 208000003493 Rhinophyma Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004066 metabolic change Effects 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 210000004115 mitral valve Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 101100316808 Arabidopsis thaliana VHA-E1 gene Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000309609 Campylorhynchus chiapensis Species 0.000 description 1
- 235000002567 Capsicum annuum Nutrition 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229930183217 Genin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019332 Heat exhaustion Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 101100232410 Homo sapiens CLNS1A gene Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 241001602180 Lamia Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000252067 Megalops atlanticus Species 0.000 description 1
- 102100020846 Methylosome subunit pICln Human genes 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001246312 Otis Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 241000897276 Termes Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000949477 Toona ciliata Species 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 101150009898 VATE gene Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- -1 bolus Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000009230 endogenous glucose production Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000010442 halite Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 201000002691 miliaria crystallina Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100001078 no known side-effect Toxicity 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940092310 salicylic acid pill Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 231100000489 sensitizer Toxicity 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229930191398 similan Natural products 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0316940A GB0316940D0 (en) | 2003-07-19 | 2003-07-19 | Treatment of skin and other medical conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200601414B true ZA200601414B (en) | 2007-04-25 |
Family
ID=27772314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200601414A ZA200601414B (en) | 2003-07-19 | 2006-02-17 | Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JP2012167103A (zh) |
| CN (2) | CN1826102A (zh) |
| DK (1) | DK1656120T3 (zh) |
| EA (1) | EA011854B1 (zh) |
| ES (1) | ES2399269T3 (zh) |
| GB (2) | GB0316940D0 (zh) |
| IL (1) | IL173227A (zh) |
| NZ (1) | NZ545365A (zh) |
| PT (1) | PT1656120E (zh) |
| ZA (1) | ZA200601414B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102198119A (zh) * | 2011-05-27 | 2011-09-28 | 翟建鹏 | 外用药贴 |
| AU2013209343B1 (en) | 2013-05-14 | 2014-04-24 | Activesignal Holding Limited | Device for the Treatment of Bone Conditions |
| CN103599093B (zh) | 2013-11-18 | 2016-06-01 | 中国医学科学院生物医学工程研究所 | 一种抗hpv药物制剂及用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2119244A (en) * | 1982-04-30 | 1983-11-16 | Alza Corp | Potassium replacement therapy |
| US4970081A (en) * | 1989-01-03 | 1990-11-13 | Sterling Drug Inc. | Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith |
| US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
| EP1429747A4 (en) * | 2001-07-10 | 2005-01-05 | Kos Life Sciences Inc | CORE FORMULATION WITH PIOGLITAZONE HYDROCHLORIDE AND A BIGUANIDE |
-
2003
- 2003-07-19 GB GB0316940A patent/GB0316940D0/en not_active Ceased
- 2003-11-20 GB GB0327006A patent/GB0327006D0/en not_active Ceased
-
2004
- 2004-07-19 CN CN 200480020770 patent/CN1826102A/zh active Pending
- 2004-07-19 NZ NZ545365A patent/NZ545365A/en not_active IP Right Cessation
- 2004-07-19 DK DK04743442.8T patent/DK1656120T3/da active
- 2004-07-19 CN CN201210302819.4A patent/CN102973946B/zh not_active Expired - Fee Related
- 2004-07-19 EA EA200600269A patent/EA011854B1/ru not_active IP Right Cessation
- 2004-07-19 PT PT47434428T patent/PT1656120E/pt unknown
- 2004-07-19 ES ES04743442T patent/ES2399269T3/es active Active
-
2006
- 2006-01-18 IL IL173227A patent/IL173227A/en not_active IP Right Cessation
- 2006-02-17 ZA ZA200601414A patent/ZA200601414B/en unknown
-
2012
- 2012-04-20 JP JP2012096514A patent/JP2012167103A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ545365A (en) | 2009-10-30 |
| CN102973946B (zh) | 2015-03-18 |
| GB0327006D0 (en) | 2003-12-24 |
| GB0316940D0 (en) | 2003-08-27 |
| DK1656120T3 (da) | 2013-03-11 |
| JP2012167103A (ja) | 2012-09-06 |
| IL173227A0 (en) | 2006-06-11 |
| EA011854B1 (ru) | 2009-06-30 |
| EA200600269A1 (ru) | 2006-08-25 |
| CN1826102A (zh) | 2006-08-30 |
| IL173227A (en) | 2013-10-31 |
| CN102973946A (zh) | 2013-03-20 |
| ES2399269T3 (es) | 2013-03-27 |
| PT1656120E (pt) | 2013-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130142851A1 (en) | Compositions Comprising Components Coated With a Liquid Impermeable but Gas Permeable Layer, Use Thereof for Treating Cutaneous and Other Exocrine Gland Diseases | |
| JP4592041B2 (ja) | 生活の質を改善する新規食品の製造法および用途 | |
| EP0103836B1 (en) | Dietary and pharmaceutical compositions comprising methylsulfonylmethane | |
| JP3806427B2 (ja) | 新規鎮痛剤 | |
| Namdev et al. | Floating Drug Delivery Systems: An emerging trend for the treatment of peptic ulcer | |
| TW200402301A (en) | Treatment of mucositis | |
| JP2006182679A (ja) | ストレス性胃炎予防・治療剤 | |
| ZA200601414B (en) | Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases | |
| WO2020056036A1 (en) | Compositions for treating gastroesophageal reflux and barrett's esophagus | |
| US11364261B2 (en) | Alleviating common cold and influenza symptoms with molecular hydrogen | |
| MXPA06000741A (es) | Composiciones que comprenden componentes recubiertos con una capa impermeable al liquido pero permeable al gas, su uso para el tratamiento de enfermedades cutaneas y otras de glandulas exocrinas | |
| CN101347463A (zh) | 一种用于预防复发和治疗胃溃疡的药物组合物 | |
| CN101313898A (zh) | 一种用于治疗胃肠道疾病的组合物 | |
| JP2010248219A (ja) | 生活の質を改善する新規医薬組成物ならびに新規食品の製法および用途 | |
| JP2001302531A (ja) | にんにく抽出物の前立腺癌と膀胱癌の予防および治療剤としての用途 | |
| JP2005239737A (ja) | 生活の質を改善する新規医薬組成物の製法および用途 | |
| CN114432446A (zh) | 抗组胺药在制备抗肿瘤药物中的应用 | |
| WO2017028775A1 (zh) | 贻贝粘蛋白用于粘膜的防护 | |
| Adams | The Mirror | |
| TWM513700U (zh) | 含多單位活性載體的口香糖 | |
| TW201703639A (zh) | 含多單位活性載體的口香糖 | |
| NZ730379A (en) | Eutectic formulations of cyclobenzaprine hydrochloride | |
| CN102526088A (zh) | 维生素b12口服制剂的改进配方及用途 | |
| TW201114432A (en) | A use of Arctium Lappa in the pharmaceutical manufacture for Inflammatory Bowel Disease prophylaxis or treatment |